[PDF][PDF] Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer
J Rinehart, AA Adjei, PM LoRusso… - Journal of clinical …, 2004 - Citeseer
J Rinehart, AA Adjei, PM LoRusso, D Waterhouse, JR Hecht, RB Natale, O Hamid…
Journal of clinical oncology, 2004•CiteseerPurpose This multicenter, open-label, phase II study was undertaken to assess the antitumor
activity and safety of the oral mitogen-activated extracellular signal regulated kinase kinase
(MEK) inhibitor, CI-1040, in breast cancer, colon cancer, non–small-cell lung cancer
(NSCLC), and pancreatic cancer.
activity and safety of the oral mitogen-activated extracellular signal regulated kinase kinase
(MEK) inhibitor, CI-1040, in breast cancer, colon cancer, non–small-cell lung cancer
(NSCLC), and pancreatic cancer.
Purpose
This multicenter, open-label, phase II study was undertaken to assess the antitumor activity and safety of the oral mitogen-activated extracellular signal regulated kinase kinase (MEK) inhibitor, CI-1040, in breast cancer, colon cancer, non–small-cell lung cancer (NSCLC), and pancreatic cancer.
Citeseer